Skip to main content
Erschienen in: Herzschrittmachertherapie + Elektrophysiologie 3/2016

08.09.2016 | Schwerpunkt

Optimal tachycardia programming in ICDs

Recommendations in the post-MADIT-RIT era

verfasst von: Dr. med. Carsten W. Israel, Tatsiana Burmistrava

Erschienen in: Herzschrittmachertherapie + Elektrophysiologie | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Optimal implantable cardioverter–defibrillator (ICD) programming can reduce the incidence of inappropriate shock therapy and improve prognosis in patients with an ICD. Only after results from randomized trials became available was the “safety first” feeling overcome that mandated early shock therapy, waived the use of antitachycardia pacing and forced shock therapy after a time of 30 s expired, even if tachycardia discriminators would have withheld the therapy. The strong evidence to limit ICD therapy to longer ventricular tachycardia (VT) should not result in individually dangerous ICD programming, particularly in patients with a high risk of slow VT (known monomorphic VT, post VT ablation, during treatment with amiodarone, very dilated left ventricle). Monitoring zones may aid to detect unexpected slow VT and to explain symptoms such as presyncope without exposing the patient to an unnecessary risk of inappropriate therapy. This review summarizes our current knowledge on optimal ICD programming and explains exactly how we should program device parameters in practice in single- or dual-chamber ICDs by different manufacturers and in different groups of patients.
Literatur
1.
Zurück zum Zitat Bänsch D, Castrucci M, Böcker D, Breithardt G, Block M (2000) Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol 36:557–565CrossRefPubMed Bänsch D, Castrucci M, Böcker D, Breithardt G, Block M (2000) Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol 36:557–565CrossRefPubMed
2.
Zurück zum Zitat Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed
3.
Zurück zum Zitat Dorian P, Philippon F, Thibault B, Kimber S, Sterns L, Greene M, Newman D, Gelaznikas R, Barr A (2004) Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 1:540–547CrossRefPubMed Dorian P, Philippon F, Thibault B, Kimber S, Sterns L, Greene M, Newman D, Gelaznikas R, Barr A (2004) Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 1:540–547CrossRefPubMed
4.
Zurück zum Zitat Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A (2013) Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 309:1903–1911CrossRefPubMed Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A (2013) Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 309:1903–1911CrossRefPubMed
5.
Zurück zum Zitat Kloppe A, Proclemer A, Arenal A, Lunati M, Martìnez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M (2014) Efficacy of long detection interval ICD settings in secondary prevention population: data from the advance III trial. Circulation 130:308–314CrossRefPubMed Kloppe A, Proclemer A, Arenal A, Lunati M, Martìnez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M (2014) Efficacy of long detection interval ICD settings in secondary prevention population: data from the advance III trial. Circulation 130:308–314CrossRefPubMed
6.
Zurück zum Zitat Lee WS, Kim J, Kwon CH, Choi JH, Jo U, Kim YR, Nam GB, Choi KJ, Kim YH (2016) Tachyarrhythmia cycle length in appropriate versus inappropriate defibrillator shocks in Brugada syndrome, early repolarization syndrome, or idiopathic ventricular fibrillation. Korean Circ J 46:179–185CrossRefPubMedPubMedCentral Lee WS, Kim J, Kwon CH, Choi JH, Jo U, Kim YR, Nam GB, Choi KJ, Kim YH (2016) Tachyarrhythmia cycle length in appropriate versus inappropriate defibrillator shocks in Brugada syndrome, early repolarization syndrome, or idiopathic ventricular fibrillation. Korean Circ J 46:179–185CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275–2283CrossRefPubMed Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275–2283CrossRefPubMed
8.
Zurück zum Zitat Poole JJE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH (2008) Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359:1009–1017CrossRefPubMedPubMedCentral Poole JJE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH (2008) Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359:1009–1017CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Rodríguez-Mañero M, Sacher F, de Asmundis C, Maury P, Lambiase PD, Sarkozy A, Probst V, Gandjbakhch E, Castro-Hevia J, Saenen J, Fukushima Kusano K, Rollin A, Arbelo E, Valderrábano M, Arias MA, Mosquera-Pérez I, Schilling R, Chierchia GB, García-Bolao I, García-Seara J, Hernandez-Ojeda J, Kamakura T, Martínez-Sande L, González-Juanatey JR, Haïssaguerre M, Brugada J, Brugada P (2016) Monomor-phic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm 13:669–682CrossRefPubMed Rodríguez-Mañero M, Sacher F, de Asmundis C, Maury P, Lambiase PD, Sarkozy A, Probst V, Gandjbakhch E, Castro-Hevia J, Saenen J, Fukushima Kusano K, Rollin A, Arbelo E, Valderrábano M, Arias MA, Mosquera-Pérez I, Schilling R, Chierchia GB, García-Bolao I, García-Seara J, Hernandez-Ojeda J, Kamakura T, Martínez-Sande L, González-Juanatey JR, Haïssaguerre M, Brugada J, Brugada P (2016) Monomor-phic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm 13:669–682CrossRefPubMed
10.
Zurück zum Zitat Roses-Noguer F, Jarman JW, Clague JR, Till J (2014) Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 11:58–66CrossRefPubMed Roses-Noguer F, Jarman JW, Clague JR, Till J (2014) Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 11:58–66CrossRefPubMed
11.
Zurück zum Zitat Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C (2014) Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol 25:52–59CrossRefPubMed Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C (2014) Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol 25:52–59CrossRefPubMed
12.
Zurück zum Zitat Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ (2005) Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 111:2898–2905CrossRefPubMed Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ (2005) Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 111:2898–2905CrossRefPubMed
13.
Zurück zum Zitat Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM (2011) Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 22:280–289CrossRefPubMed Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM (2011) Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 22:280–289CrossRefPubMed
14.
Zurück zum Zitat Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, Adkisson WO (2001) Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 104:796–801CrossRefPubMed Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, Adkisson WO (2001) Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 104:796–801CrossRefPubMed
15.
Zurück zum Zitat Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ (2004) Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators. Circulation 110:2591–2596CrossRefPubMed Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ (2004) Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators. Circulation 110:2591–2596CrossRefPubMed
16.
Zurück zum Zitat Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK (2008) Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 52:541–550CrossRefPubMed Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK (2008) Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 52:541–550CrossRefPubMed
17.
Zurück zum Zitat Wilkoff BL (2010) Late breaking clinical trials: programming strategies associated with shock reduction in 88804 implantable defibrillator patients. Heart Rhythm Society 31st Annual Scientific Sessions, Denver, May 2010 Wilkoff BL (2010) Late breaking clinical trials: programming strategies associated with shock reduction in 88804 implantable defibrillator patients. Heart Rhythm Society 31st Annual Scientific Sessions, Denver, May 2010
18.
Zurück zum Zitat Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, Mcguire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S (2016) 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace 18:159–183CrossRefPubMed Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, Mcguire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S (2016) 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace 18:159–183CrossRefPubMed
Metadaten
Titel
Optimal tachycardia programming in ICDs
Recommendations in the post-MADIT-RIT era
verfasst von
Dr. med. Carsten W. Israel
Tatsiana Burmistrava
Publikationsdatum
08.09.2016
Verlag
Springer Medizin
Erschienen in
Herzschrittmachertherapie + Elektrophysiologie / Ausgabe 3/2016
Print ISSN: 0938-7412
Elektronische ISSN: 1435-1544
DOI
https://doi.org/10.1007/s00399-016-0459-x

Weitere Artikel der Ausgabe 3/2016

Herzschrittmachertherapie + Elektrophysiologie 3/2016 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.